Analyst consensus rating
TransMedics Group Analyst Rating: Buy
Direct answer
TransMedics Group's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $98.73.
Forecast evidence checked October 27, 2026.
Get free TransMedics Group email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $69.73
- Average price target
- $98.73
- High price target
- $125.00
- Low price target
- $65.00
- Low target gap
- -6.8%
- Target upside
- +41.6%
- High target gap
- +79.3%
- Target range width
- 86%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for TransMedics Group?
TransMedics Group has a verified Buy consensus. The same dataset has an average price target of $98.73.
How far are TransMedics Group's low and high targets from the recorded price?
The low target implies -6.8%, while the high target implies +79.3%.
How many analysts are included in TransMedics Group's consensus?
The verified consensus includes 11 analysts.
How is TransMedics Group's target upside or downside calculated?
The average target of $98.73 is divided by the recorded price of $69.73, then one is subtracted to produce +41.6%. This does not guarantee a future return.
When was TransMedics Group's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.